These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

678 related items for PubMed ID: 30610862

  • 1. Fecal Microbiota Transplantation Is Superior to Fidaxomicin for Treatment of Recurrent Clostridium difficile Infection.
    Hvas CL, Dahl Jørgensen SM, Jørgensen SP, Storgaard M, Lemming L, Hansen MM, Erikstrup C, Dahlerup JF.
    Gastroenterology; 2019 Apr; 156(5):1324-1332.e3. PubMed ID: 30610862
    [Abstract] [Full Text] [Related]

  • 2. Fidaxomicin versus vancomycin for Clostridium difficile infection.
    Louie TJ, Miller MA, Mullane KM, Weiss K, Lentnek A, Golan Y, Gorbach S, Sears P, Shue YK, OPT-80-003 Clinical Study Group.
    N Engl J Med; 2011 Feb 03; 364(5):422-31. PubMed ID: 21288078
    [Abstract] [Full Text] [Related]

  • 3. Fecal microbiota transplantation for the treatment of recurrent Clostridioides difficile (Clostridium difficile).
    Minkoff NZ, Aslam S, Medina M, Tanner-Smith EE, Zackular JP, Acra S, Nicholson MR, Imdad A.
    Cochrane Database Syst Rev; 2023 Apr 25; 4(4):CD013871. PubMed ID: 37096495
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. A network meta-analysis of randomized controlled trials exploring the role of fecal microbiota transplantation in recurrent Clostridium difficile infection.
    Rokkas T, Gisbert JP, Gasbarrini A, Hold GL, Tilg H, Malfertheiner P, Megraud F, O'Morain C.
    United European Gastroenterol J; 2019 Oct 25; 7(8):1051-1063. PubMed ID: 31662862
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Cost-effectiveness analysis of fecal microbiota transplantation for recurrent Clostridium difficile infection in patients with inflammatory bowel disease.
    You JHS, Jiang X, Lee WH, Chan PKS, Ng SC.
    J Gastroenterol Hepatol; 2020 Sep 25; 35(9):1515-1523. PubMed ID: 32017248
    [Abstract] [Full Text] [Related]

  • 9. Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection in patients 60 years and older (EXTEND): a randomised, controlled, open-label, phase 3b/4 trial.
    Guery B, Menichetti F, Anttila VJ, Adomakoh N, Aguado JM, Bisnauthsing K, Georgopali A, Goldenberg SD, Karas A, Kazeem G, Longshaw C, Palacios-Fabrega JA, Cornely OA, Vehreschild MJGT, EXTEND Clinical Study Group.
    Lancet Infect Dis; 2018 Mar 25; 18(3):296-307. PubMed ID: 29273269
    [Abstract] [Full Text] [Related]

  • 10. Fecal microbiota transplantation for recurrent Clostridium difficile infection in patients with solid organ transplants: an institutional experience and review of the literature.
    Lin SC, Alonso CD, Moss AC.
    Transpl Infect Dis; 2018 Dec 25; 20(6):e12967. PubMed ID: 30011107
    [Abstract] [Full Text] [Related]

  • 11. Clinical outcomes of fidaxomicin vs oral vancomycin in recurrent Clostridium difficile infection.
    Tieu JD, Williams RJ, Skrepnek GH, Gentry CA.
    J Clin Pharm Ther; 2019 Apr 25; 44(2):220-228. PubMed ID: 30350418
    [Abstract] [Full Text] [Related]

  • 12. Randomized clinical trial to evaluate the effect of fecal microbiota transplant for initial Clostridium difficile infection in intestinal microbiome.
    Camacho-Ortiz A, Gutiérrez-Delgado EM, Garcia-Mazcorro JF, Mendoza-Olazarán S, Martínez-Meléndez A, Palau-Davila L, Baines SD, Maldonado-Garza H, Garza-González E.
    PLoS One; 2017 Apr 25; 12(12):e0189768. PubMed ID: 29261736
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. A pilot study to assess bacterial and toxin reduction in patients with Clostridium difficile infection given fidaxomicin or vancomycin.
    Thabit AK, Alam MJ, Khaleduzzaman M, Garey KW, Nicolau DP.
    Ann Clin Microbiol Antimicrob; 2016 Apr 12; 15():22. PubMed ID: 27071986
    [Abstract] [Full Text] [Related]

  • 15. Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection in Patients at Increased Risk for Recurrence.
    Gerding DN, Kelly CP, Rahav G, Lee C, Dubberke ER, Kumar PN, Yacyshyn B, Kao D, Eves K, Ellison MC, Hanson ME, Guris D, Dorr MB.
    Clin Infect Dis; 2018 Aug 16; 67(5):649-656. PubMed ID: 29538686
    [Abstract] [Full Text] [Related]

  • 16. New and emerging therapies in treatment of Clostridium difficile infection.
    Goyal H, Perisetti A, Rehman MR, Singla U.
    Eur J Gastroenterol Hepatol; 2018 Jun 16; 30(6):589-597. PubMed ID: 29521664
    [Abstract] [Full Text] [Related]

  • 17. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial.
    Cornely OA, Crook DW, Esposito R, Poirier A, Somero MS, Weiss K, Sears P, Gorbach S, OPT-80-004 Clinical Study Group.
    Lancet Infect Dis; 2012 Apr 16; 12(4):281-9. PubMed ID: 22321770
    [Abstract] [Full Text] [Related]

  • 18. Fecal microbiota transplantation for treatment of recurrent C. difficile infection: An updated randomized controlled trial meta-analysis.
    Hui W, Li T, Liu W, Zhou C, Gao F.
    PLoS One; 2019 Apr 16; 14(1):e0210016. PubMed ID: 30673716
    [Abstract] [Full Text] [Related]

  • 19. An Open-Label, Randomized Trial Comparing Fidaxomicin With Oral Vancomycin for the Treatment of Clostridioides difficile Infection in Hospitalized Patients Receiving Concomitant Antibiotics for Concurrent Infections.
    Rao K, Zhao Q, Bell J, Krishnan J, Henig O, Daniel J, Sawaya K, Albin O, Mills JP, Petty LA, Gregg K, Kaul D, Malani AN, Pogue J, Kaye KS.
    Clin Infect Dis; 2024 Feb 17; 78(2):277-282. PubMed ID: 37797310
    [Abstract] [Full Text] [Related]

  • 20. Single centre clinical experience with fidaxomicin in the treatment of Clostridium difficile infection in Slovakia.
    Novotný M, Jarčuška P, Gombošová L, Hockicko J, Hockicková I, Rovňáková A, Zahornacký O, Schréter I, Dorko E, Rimárová K.
    Cent Eur J Public Health; 2018 Dec 17; 26 Suppl():S76-S80. PubMed ID: 30817879
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.